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ABSTRACT
PRODUCTION OF A MONOCLONAL ANTIBODY AGAINST THE ALPHA 4 BETA
7 INTEGRIN
by Asima Khan
This study describes an attempt to produce a monoclonal antibody (mAb) against
the human alpha 4 beta 7 (a4(37) gut-homing integrin found on lymphocytes. The
recruitment of lymphocytes via the a4[37 receptor to the gut has been associated with
inflammatory bowel disease (IBD). A novel immunization strategy was employed in
generating polyclonal antibodies (pAb) in C57BL/6 mice. (37 knock-out (K/O) mice were
immunized with (37 wild-type (WT) mouse splenocytes with cell-surface (37. As a final
boost, mice were injected with human peripheral blood mononuclear cells (PBMC), with a
rationale of boosting epitopes shared between murine and human (37. Immune sera and
clones generated by hybridoma technology were screened using the enzyme-linked
immunosorbent assay (ELISA) and flow cytometry. Despite binding to both mouse cells
and PBMCs expressing a4(37, the mAb produced is unlikely to be anti-a4(37 because it
generated a different staining pattern than the positive control, ACT-1, on T cell subsets
that migrate to the gut.
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PREFACE
The following thesis consists of three chapters and the appendices. The first
chapter is a detailed introduction of inflammatory bowel disease, the mechanism of
lymphocyte homing, the role of the alpha 4 beta 7 integrin, strategies for treating the
disease and our research goals. The second chapter is presented in manuscript format in
accordance with guidelines from the Journal of Immunology. Chapter II has its own
separate list of references cited. Chapter III is a detailed discussion of the results and
future direction for the study. Chapter III is followed by a list of references cited for both
Chapters I and III. The appendices provide supplementary materials associated with the
research.
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CHAPTER I
INTRODUCTION
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INTRODUCTION
Inflammatory Bowel Disease
IBD is comprised of Crohn's disease (CD) and ulcerative colitis (UC), two chronic
intestinal inflammatory conditions. UC involves inflammation of the inner lining of the
large intestine or colon while CD extends deeper into the intestinal wall and commonly
affects both the large and small intestine and other organs in the digestive tract (1).
Patients typically experience lifelong recurring symptoms such as bloody diarrhea and
abdominal cramping during bowel movements. There are an average of 6 new cases of
CD and 12 new cases of UC per 100,000 people per year (2, 3).
Although the etiology of IBD is still elusive, a genetic predisposition,
environmental factors and an aberrant immune response are all implicated in influencing
IBD development (4). Studies of IBD in recent years have led to a better understanding of
its pathogenesis and various aspects of the regulation of the mucosal immune system. IBD
is manifested by chronic mucosal inflammation and an influx of inflammatory leukocytes.
Basically, a heightened mucosal immune reaction occurs in response to harmless bacterial
antigens (5). A variety of immunologic defects, such as an excessive T and B cell
response, have been identified.
In healthy individuals, the immune system is able to distinguish between
commensal bacteria that maintain a symbiotic relationship with their hosts and pathogens
(6). Receptors expressed by dendritic cells (DC), toll-like receptors (TLR), recognize
structurally conserved molecular patterns found on microbes. Using TLRs, DCs are able to
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polarize naive T cell differentiation into regulatory T cells (in response to the commensal
bacteria) or into effector T cells (in response to pathogens) (4).
In IBD, several abnormalities of the mucosal immune system have been cited (7).
First of all, the expression of TLRs goes awry. TLRs that react in the presence of
pathogens such as TLR4 are up-regulated, while those that maintain homeostasis such as
TLR3 are down-regulated and suppressed (4). Also, DCs falsely respond to indigenous
microbial antigens and undergo differentiation leading to disproportionate populations of
effector T cells and pro-inflammatory responses (8). Pro-inflammatory cytokines such as
IL-12, IL-18, IL-23, tumor necrosis factor alpha (TNF-a) and IFN yare released and upregulate the expression of adhesion molecule ligands on the vascular endothelium
encouraging leukocyte adhesion and extravasation into the tissue (9-11). T and B
lymphocytes and macrophages are among the leukocytes that respond to these chemotactic
signals. Upon reaching the antigen site, macrophages then release chemokines that
accumulate at endothelial cell surfaces and attract more inflammatory leukocytes,
continuing the cycle. An interplay of all these immunologic events leads to perpetual
inflammation in what is known as IBD (5).
Lymphocyte Homing
The recruitment process of lymphocytes to the gut involves several sequential steps
(Fig. 1) (12). The cells are in transit, under high flow conditions in the bloodstream and
must come to an arrest and proceed through the vasculature to the tissue of interest (13).
The first step is the primary adhesion which is transient and reversible, accomplished by
selectins found on lymphocytes binding their ligands on the endothelial cell surface (14).
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This interaction allows for loose rolling of the lymphocytes along the vessel wall and
successfully slows their transit. Shortly after the initial contact, the lymphocytes are
activated by chemokines on the endothelial surface interacting with chemokine receptors
found on the cells (15, 16). This interaction increases the affinity of integrin receptors for
their adhesion molecules and promotes their binding. Specifically, the oc4(37 integrin
receptor on the lymphocyte cell-surface binds the mucosal addressin cell adhesion
molecule-1 (MAdCAM-1) found on the endothelium. This results in an activationdependent arrest and firmly adheres the lymphocytes to the endothelium. Finally, cells
undergo transmigration, the passage of lymphocytes through intact vessel walls to the
surrounding tissue (17-19).
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FIGURE 1. A multi-step model of leukocyte extravasation. This figure was reprinted
with permission from Dr. Patricia Celie, Department of Molecular Cell Biology and
Immunology, VU University Medical Center, Amsterdam, the Netherlands. Endothelial
cells express selectin ligands triggered by inflammation. Selectins are expressed on
leukocytes, such as L-selectin (not shown), and transiently interact with their ligands
resulting in a rolling motion over the endothelium. This effectively slows the cells down
which are in transit in the bloodstream. Then, chemokines generated at the endothelial
surface, such as CCL25 (not shown), bind with chemokine receptors found on the
leukocytes, such as CCR9 (not shown), resulting in leukocyte activation. Shortly
afterwards, the leukocyte integrins, such as a4p7 (not shown), are activated by binding to
their ligands, such as MAdCAM-l(not shown), on the endothelium. This results in firm
adhesion of the cell to the endothelial surface. Transmigration of the cell across the
endothelial barrier follows.
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Integrins and a4/37
The integrins, a family of cell adhesion receptors, are comprised of two noncovalently linked transmembrane glycoprotein subunits, a and p, that form heterodimers
(20). Intergin receptors mediate interactions of the cells with endothelial tissue via
ligands called intercellular adhesion molecules (ICAMs) (21). Structure and function
analysis of the integrin (37 subunit has identified a small region (residues 46-386) that
accounts for a4(37 binding specificity to its ligand, MAdCAM-1 (21). The oc4(37 integrin is
expressed on lymphocytes that are destined to migrate to mucosal surfaces, namely CD4+,
CD8+ T cells, IgA+ plasma cells and plasmablasts (13, 22, 23).
Strategies for IBD Treatment
Conventionally, immunosuppressive agents that non-specifically control
inflammation have been used to treat IBD (24, 25). Recently, therapies that involve
generating mAbs against molecules specifically involved in the inflammatory cascade have
been introduced (1). Infliximab, an anti-TNF-a mAb is currently used as therapy for CD
(26). Other anti-cytokine mAbs that inhibit IFN-y and IL-12 are still being investigated.
Antibodies that inhibit molecules involved in the migration of leukocytes to the gut have
also been developed. In animal models, mAbs against the (37 integrin subunit (FEB504)
and MAdCAM-1 (MECA-367) were able to reduce inflammation in the mouse colon (27).
For humans, Natalizumab is a humanized anti-a4 integrin mAb that is able to prevent
oc4(37/MAdCAM-1 interactions. There is one humanized mAb, MLN-02 (also known as
ACT-1), that specifically recognizes human a4(37 (28). This mAb, however, is not
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commercially available for research purposes. In this project, we attempt to produce a
mouse mAb against the human a4(37 integrin to fulfill this need.
Research Goals
We adopted a novel immunization strategy to elicit a potent immune response
against the (37 subunit of the a4(37 heterodimer. It involved immunizing (37 K/O mice with
WT mouse splenocytes with naturally-occurring (37. The murine (37 subunit was chosen as
the antigen because residues 46-386 of the murine and human (37 subunit (which account
for a4(37 specificity for MAdCAM-1) are 92% homologous (21). This homology makes
the murine {37 suitable for eliciting an immune response that can be boosted with human
(37. The antibody produced would have a desired specificity to shared epitopes of mouse
and human (37, in conformation with a4. Such an antibody could be used to test the
hypothesis that IBD is associated with elevated blood levels of gut-homing lymphocytes, in
particular plasmablasts. It would enable the tracking of these gut-specific plasmablasts in
patient blood samples. Along with being linked to the disease state, plasmablast blood
levels detected by such an antibody and other plasmablast markers could be used to
monitor patient response to IBD therapy.
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Abstract

This study describes the production of a murine monoclonal antibody (mAb3)
against the human alpha 4 beta 7 (a4(37) gut-homing integrin receptor found on both T and
B lymphocytes. The recruitment of lymphocytes via the a4(37 receptor to the gut has been
associated with chronic inflammatory bowel disease (IBD). There is currently only one
anti-oc4(37 mAb in existence, but it is not commercially available. Studies involving this
receptor are in need of such an antibody (Ab). A novel immunization strategy was
employed in generating the desired polyclonal antibodies (pAb) in C57BL/6 mice.
(37 knock-out (K/O) mice were immunized with (37 wild-type (WT) mouse splenocytes
with naturally occurring cell-surface (37. As a final boost, mice were injected with human
peripheral blood mononuclear cells (PBMC), with a rationale of boosting epitopes shared
between murine and human (37. Immune sera and supernatants of several clones generated
by hybridoma technology were tested using enzyme-linked immunosorbent assays
(ELISA) and flow cytometry. In flow cytometric screening assays, the staining pattern of
the Abs on PBMC expressing human (37 versus a mouse T cell line over-expressing
a4(37 molecules (TK1) was evaluated. Despite binding to both TK1 cells and PBMCs, the
mAb produced is unlikely to be anti-a4(37 because it generated a different staining pattern
than the positive control, ACT-1, on T cell subsets that migrate to the gut.
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Introduction
Inflammatory Bowel Disease
IBD is comprised of Crohn's disease (CD) and ulcerative colitis (UC), two chronic
intestinal inflammatory conditions that currently affect about 1.4 million people in the
United States (1). Although the etiology of IBD is still elusive, IBD is manifested by
chronic mucosal inflammation that results from an aberrant immune response and an influx
of inflammatory lymphocytes to the gut. This heightened mucosal immune reaction occurs
in response to harmless bacterial antigens (2).
In healthy individuals, the immune system is able to distinguish between
commensal bacteria that maintain a symbiotic relationship with their hosts and pathogens
(3). In IBD however, DCs falsely respond to indigenous microbial antigens and mature,
inducing effector T cell and pro-inflammatory responses (4). Pro-inflammatory cytokines
such as IL-12, EL-18, IL-23, tumor necrosis factor alpha (TNF-a) and IFN y are released
and up-regulate the expression of adhesion molecule ligands on the vascular endothelium
encouraging leukocyte adhesion and extravasation into the tissue (5-7). T and B
lymphocytes and macrophages are among the leukocytes that respond to these chemotactic
signals. Upon reaching the antigen site, macrophages then release chemokines that
accumulate at endothelial cell surfaces and attract more inflammatory leukocytes,
continuing the cycle. An interplay of all these immunologic events leads to perpetual
inflammation in what is known as IBD (2).
The recruitment process of lymphocytes to the gut involves several sequential steps.
The cells are in transit, under high flow conditions in the bloodstream and must come to an
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arrest and proceed through the vasculature to the tissue of interest (8, 9). Primary adhesion
which is transient and reversible is accomplished by selectins such as L-selectin found on
lymphocytes binding their ligands on the endothelial cell surface (10). This interaction
allows for loose rolling of the lymphocytes along the vessel wall and successfully slows
their transit. Lymphocytes are then activated by an interaction between chemokines
generated on the endothelial surface such as CCL25 and chemokine receptors such as
CCR9 found on the cells (11, 12). This interaction increases the affinity of integrin
receptors for their adhesion molecules and promotes their binding. Specifically, the
a4p7 integrin on the lymphocyte cell-surface binds the mucosal addressin cell adhesion
molecule-1 (MAdCAM-1) found on the endothelium. This results in an activationdependent arrest and firmly adheres the lymphocytes to the endothelium. Finally, cells
undergo transmigration, the passage of lymphocytes through intact vessel walls to the
surrounding tissue (13-15).
Structure and function analysis of the integrin [37 subunit of the oc4(37 heterodimer
identified a small region (residues 46-386) that accounts for oc4p7 binding specificity to its
ligand, MAdCAM-1 (16). The oc4|37 integrin is expressed on lymphocytes that are
destined to migrate to mucosal surfaces, namely CD4+, CD8+ T cells, IgA+ plasma cells
and plasmablasts (9, 17, 18).
In order to study oc4p7 in association with IBD, an attempt was made to generate a
mAb against the integrin. A novel immunization strategy was adopted for eliciting a
potent immune response against the (37 subunit of the a4p7 heterodimer. It involved
immunizing p7 K/O mice with WT mouse splenocytes with naturally-occurring P7. The
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murine (37 subunit was chosen as the antigen because residues 46-386 of the murine and
human (37 subunit (which account for a4(37 specificity for MAdCAM-1) are 92%
homologous (16). This homology makes the murine (37 suitable for eliciting an immune
response that can be boosted with human (37. The antibody produced would preferentially
be against shared epitopes of mouse and human (37, in conformation with a4.
The purpose of such an antibody was to test the hypothesis that IBD is associated
with elevated blood levels of gut-homing lymphocytes, in particular plasmablasts. It would
enable the tracking of these gut-specific plasmablasts in patient blood samples. Along with
being linked to the disease state, plasmablast blood levels detected by such an antibody and
other plasmablast markers could be used to monitor patient response to IBD therapy.
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Materials and Methods
All studies using animal and human subjects have been reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) (Protocol #904) and Human
Subjects-Institutional

Review Board (IRB) (Protocol #F0902030) at San Jose State

University, San Jose, CA.
Cells and media
TK1 is a CD8+ T lymphoma cell line over-expressing a4[37 that originated from a
spontaneous thymic lymphoma in an AKR/Cum mouse [American Type Culture
Collection (ATCC) CRL-2396] (a gift of Eugene Butcher's, Stanford University).
Cryopreserved PBMC were also a gift from Dr. Butcher's lab. They were isolated by a
Ficoll gradient. Sp2/0 myeloma cells were obtained from San Jose State University. All
cells were stored in liquid nitrogen until needed, then maintained in culture in
supplemented RPMI 1640 [2 mM L-glutamine (Lonza), 10% fetal calf serum (FCS)
(Invitrogen), penicillin (10,000 U/ml)/streptomycin (10,000 |ig/ml)/ amphotericin B (25
jig/ml) (ThermoScientific), 1 mM sodium pyruvate (ThermoScientific) and 1 mM nonessential amino acids (NEAA) (Lonza)]. Fresh splenocytes for screening assays and
immunizations were aseptically removed from female C57BL/6 [37 WT and/or
(37 K/O mice via splenectomies. Cells were prepared by pressing spleens through a 40
|i.m nylon mesh strainer (BD Biosciences) while washing with supplemented RPMI 1640.
Red blood cells in the mixture were lysed with 3 ml of red blood cell lysis buffer (8.3 g/L
ammonium chloride in 0.01M Tris-HCl buffer, pH 7.5) (Sigma) for 3 min. The
remaining cells were then washed twice with phosphate buffered saline (PBS) and
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counted. Feeder layer cells (peritoneal macrophages) were obtained by injecting 10 ml of
supplemented RPMI 1640 into the peritoneal cavity of a BALB/c mouse with a 22 gauge
needle and 10 ml syringe, massaging the abdomen and then withdrawing the fluid.
Immunizations
Three 6 wk old female C57BL/6 [37 K/O mice (identified as Mouse L, Mouse LR
and Mouse R) were first immunized subcutaneously (s.c.) with an emulsion of 200 (il of
complete Freund's adjuvant (CFA) (Sigma) and 100 X 106 (37 WT mouse splenocytes.
Subsequently, mice were immunized s.c. every 2 wks for approximately 8 wks with an
emulsion of 200 |J.l of incomplete Freund's adjuvant (IFA) (Sigma) and an average of 70
X 106 cells per mouse. Approximately 2 wks after the last immunization with (37 WT
splenocytes, mice were bled and sera were tested by ELISA and flow cytometry assays to
assess pAb titers. Mice received their last immunization intravenously or
intraperitoneally with 60 X 106 PBMC (thawed and washed once with PBS) in 200 |ll
PBS, 3-4 days before fusion. A flow-chart summary of the immunization strategy is
shown in Fig. 2.

07 wild-type
C56BL/6 mouse

Harvest WT mouse
splenocytes with cellsurface (37.

Inject into CS7BL/6
07 K/O mice. Mice
produce pAbs against
WT mouse 07.

07 K/O
cells lack
07.

Human 0'

PBMC with human cellsurface (37, as booster
immunization

Inject into mice 3-4 days
before fusion.

Mice produce Abs against
shared mouse and human
epitopes of (37.

/

ELISA and FACS analysis
performed on immune sera to
confirm the presence of pAb
against 07.

Harvest spleens from
immunized 07 K/O
mice.

3

r -k H
Fuse cells using PEG.

Select for hybridomas on HAT media, then screen for anti07 antibody production by ELISA and flow cytometry.

FIGURE 2. Flow-chart summary of the
immunization strategy.
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Ab titration using ELISA and flow cytometry
ELISA: An indirect cell-based ELISA was performed on U-bottom 96-well plates
(Costar). One to five hundred thousand TK1 cells were seeded per well and blocked at
room temperature (RT) for 40 min with 150 (il/well blocking buffer (2% FCS, 0.05%
Tween-20 in PBS). Plates were then centrifuged (300 X g for 5 min), decanted and the
cells resuspended in 100 |il/well blocking buffer supplemented with 5% goat serum,
followed by incubation at RT for another 20 min. Plates were then centrifuged, decanted
and cells were resuspended in 100 |ll/well primary Ab [negative control (anti-Listeria
monocytogenes pAb), preimmune and immune sera] in blocking buffer. Two-fold serial
dilutions of each of the primary Abs were made starting with 1/50, followed by
incubation at 4°C for 1 h. Cell pellets were disrupted by gently shaking plates every 15
min on a plate shaker (ThermoScientific) for 30 s. After the incubation, cells were
washed 3 times with 150 [ll/well blocking buffer. One hundred microliters per well of
alkaline phosphatase-conjugated secondary Ab (goat anti-mouse IgG, whole molecule)
(Sigma) (1/1000) diluted in blocking buffer was added and cells were incubated for at
4°C for 1 h. Cells were washed 2 times with 150 (ll/well of blocking buffer and a third
time with PBS. Plates were decanted and developed with 175 }il/well of alkalinephosphatase substrate (1.0 mg/ml p-Nitrophenyl phosphate and 0.2 M Tris buffer)
(Sigma) dissolved according to the manufacturer's instructions. Thirty to forty-five min
later when color had developed, absorbance was determined at 405 nm.
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Flow cytometry analysis: One million TK1 cells/tube were kept on ice and
blocked with a 1/50 dilution of goat serum in staining buffer (SB) [1% FCS, 0.1%
sodium azide (Sigma) in PBS] and incubated for 10 min at 4°C. Cells were centrifuged
(300 X g, 5 min), resuspended with a mixture of goat serum (1/50) and two-fold serial
dilutions of primary Abs [negative control (anti-Listeria monocytogenes pAb), positive
control (ACT-1, mouse anti-human a4p7; FIB504, rat anti-mouse (37), preimmune and
immune sera] and incubated at 4°C for 30 min. Hybridoma supernatants of the positive
control Abs were a gift from Dr. Butcher's lab, Stanford University. Cells were then
washed 3 times with SB and resuspended with secondary-labeled Ab, goat anti-mouse
IgG or goat anti-rat IgG conjugated to phycoerythrin (PE) (Jackson ImmunoResearch)
and incubated in the dark at 4°C for 30 min. Tubes were then washed 3 times with SB.
Cells were fixed in 500 (ll/tube of 1% formaldehyde (formalin diluted in PBS) (Sigma)
and analyzed by flow cytometry (FACSCalibur; BD Biosciences). Ten thousand events
were acquired in all flow cytometry experiments. Quadrants on dot plots in all flow
cytometry experiments were set according to the secondary-labeled Ab control. The FL2
fluorescence detector in the cytometer is able to detect PE which emits a fluorescence
signal near 585 nm.
Polyclonal Ab sera assessment for (57 specificity
Immune sera were assessed by FACS analysis for p7 specificity using a mixture
of TK1 cells and PBMC, 5 X 10 5 each per tube. Frozen PBMC were thawed, washed
once with RPMI 1640 to remove DMSO and counted. Staining of PBMC was performed
as described above for TK1 cells except 1/200 dilutions of preimmune and immune sera
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were used as primary Abs. Sera were also tested by flow cytometry on [37 WT and
(37 K/O splenocytes. Splenocytes were prepared as described above. Two identical
experiments were run in parallel with the two types of splenocytes. The assay was also
identical to the one described above for TK1 cells except for some additional steps. A
1/200 dilution of each mouse serum was used. After washing to remove unbound
secondary Ab, cells were blocked with a mixture of rat and mouse sera (eBioscience and
Harlan Bioproducts, respectively) diluted 1/50 and incubated at 4°C in the dark for 10
min. Cells were washed three times and a mixture of rat serum (1/50), mouse serum
(1/50) and a 1/200 dilution of rat anti-mouse CD45R/B220 Ab conjugated to FITC (BD
Pharmingen) was added. Anti-B220 Ab was used to exclude B cells. After a 20 min
incubation at 4°C in the dark, cells were washed as before, resuspended in 500 jxl/tube of
1% formaldehyde and analyzed on the FACSCalibur. FITC is detected by the FL1
fluorescence detector in the cytometer which detects fluorescence signals near 530 nm.
Fusion
Three separate fusions were performed using splenocytes from the 3 immunized
mice (L, LR and R). Three to four days after the final booster, the spleen was removed
and processed as described above. Healthy Sp2/0 myeloma cells in log phase of growth
were mixed with splenocytes at a ratio of 1:3. After centrifugation, 2 ml of 50%
polyethylene glycol (PEG) (Sigma) in plain RPMI-1640 (lacks FCS, sodium pyruvate
and NEAA) was slowly added to the cell mixture pellet over 1 minute, followed by 2 ml
of plain RPMI-1640 (over 5 min) and 20 ml of plain RPMI-1640 slowly but not dropwise. Cells were centrifuged and resuspended in RPMI-1640 supplemented with 20%
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FCS and 10% hybridoma cloning factor (CF) (BioVeris Corp) to obtain a concentration
of 1.3 X 106 cells/ml. Five different concentrations of fused cells (1 X 105, 5 X 104, 2.5
X 104, 1 X 104 and 5 X 103 cells/well) resuspended in supplemented RPMI (150 fil/well
final volume) were co-cultured in 96-well flat-bottom plates (Corning Costar 3596) with
4 X 1 0 cells/well of peritoneal macrophages (as feeder cells). The day after the fusion,
50 fil/well of 4X HAT medium [hypoxanthine, aminopterin and thymidine (HAT)
supplement (MP BioMedicals) mixed with RPMI-1640 with 2 mM L-glutamine, 20%
FCS, penicillin (10,000 U/ml)/ streptomycin (10,000 (Xg/ml)/ amphotericin B (25 (ig/ml),
1 mM sodium pyruvate, 1 mM NEAA and 50 |iM P-mercaptoethanol] was added to the
cells to generate IX HAT.
Hybridoma

screening

Hybridomas were microscopically screened 10-12 days post-fusion. Supernatants
from single clones occupying at least one third of the bottom of the well were tested by
ELISA and flow cytometry as described above, using TK1 cells for the ELISA and a
mixture of TK1 cells and PBMC for the flow cytometric assays. Positive clones (those
that had atleast 1.6 times higher absorbance values than the preimmune serum for the
ELISA and considerably brighter staining in flow cytometry) were subcloned by the
limiting dilution method.
Limiting dilution
Twenty-five microliters of resuspended hybridoma cells in supplemented HAT
media were removed from the positive clone wells and added to a well on a new 96-well
plate containing 100 (ll of IX HT media (Mediatech) (prepared the same as the HAT

22

media except aminopterin was excluded). Sequential dilutions (1/5) were performed for
a few additional wells containing 100 |xl of HT media. The contents of a well with an
average of 25 cells (counted microscopically) were transferred to 40 ml of HT media
(with 5% CF), mixed and plated onto three 96-well flat-bottom plates (100 (il/well in two
plates and 200 (il/well in the third plate).
Flow cytometry analysis of subclones for [37 Specificity
Subclones from the original positive hybridomas were analyzed for [37 specificity
with flow cytometry using screening assays as described above. They were tested on a
mixture of PBMC and TK1 cells and on [37 WT and (37 K/O splenocytes. Positive clones
were cryopreserved at -80°C for 2 days and then transferred to liquid nitrogen. One to
two million cells per vial were frozen in 1 ml of freezing media (50% RPMI-1640, 40%
FCS, 10% DMSO).
Competition assays
Positive clones were analyzed in competition assays to see if the Abs they
produced could block positive control Abs from binding TK1 cells or PBMC. One
million TK1 cells/tube were first exposed for 30 min to primary Abs, washed and then
cells were incubated with 50 |ll of FEB504 for 30 min. The cells were washed again 3
times and resuspended in 100 |il of a 1/100 dilution of goat anti-rat secondary Ab
conjugated to PE and incubated at 4°C for 30 min. Cells were then fixed with 1%
formaldehyde and analyzed by flow cytometry. For experiments using PBMC, 1 X 106
PBMC/tube were blocked with 0.5 (il of goat serum for 10 min. After centrifugation
(300 X g, 5 min), 50 Jul of primary Abs [FEB504 positive control Ab (supernatant) or
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preimmune or immune sera (diluted 1/200 in SB) or hybridoma supernatants] were added
to the cells and incubated at 4°C for 30 min. Cells were then washed and stained with 5
JLXI

of ACT-1 conjugated to allophycocyanin (APC) (a gift of Eugene Butcher's, Stanford

University) together with 10 jil of mouse blocking serum. They were allowed to incubate
for 20 min at 4°C in the dark and then washed. Finally, the cells were resuspended in 500
fil/tube of 1% formaldehyde and acquired by flow cytometry. The FL4 fluorescence
detector in the cytometer is able to detect APC which emits a fluorescence signal near
675 nm.
Multi-color assay
A multi-color FACS analysis was performed on human PBMC. Hybridoma
subclone supernatants and the polyclonal Ab serum were used to stain PBMC and their
staining pattern was compared with the staining pattern generated by the human antia4(37 antibody (ACT-1). One million PBMC were blocked with 0.5 |il goat serum for 10
min. Fifty microliters of primary Ab was added to tubes with cells and incubated at 4° C
for 30 min. Cells were washed with 3 ml of SB then resuspended with goat anti-mouse
secondary Ab conjugated to PE. They were incubated for 30 min (in the dark) at 4° C
then washed again with 3 ml of SB. A master mix composed of 5 |il/tube anti-CD45RA
FITC, 10 jil/tube biotinylated anti-cutaneous lymphocyte antigen (CLA), 1 |il/tube antiCD4 APC and 5 (il/tube anti-CD62L Cy7 APC was made and added to the cells to isolate
the desired subset of cells. After a 20 min incubation at 4° C (in the dark), cells were
washed again with 3 ml of SB. Finally, 1.5 fll/tube streptavidin Cy7 PE were added to
the tubes that contained biotinylated primary Abs and incubated for another 20 min.
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After a final 3 ml wash, cells were resuspended with 500 |il/tube SB and analyzed on a
BD FACSAria flow cytometer (at the VA hospital, Palo Alto/Stanford University flow
cytometry facility).
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Results
EVALUATION OF POLYCLONAL AB SERA
Assessment ofpAb titers by ELISA and flow cytometry using /37-rich TK1 cells
(37 K/O mice were immunized with (37 WT mouse splenocytes. Immune sera
from the mice were tested during the immunization process for pAb titer on TK1 cells
using two methods: ELISA and flow cytometry (Fig. 3). Absorbance values for the
immune serum dilutions (red bars) were higher than the preimmune serum dilutions
(green bars) (Fig. 3A), indicating an immune response against the (37 found on WT
splenocytes. In flow cytometry experiments, three dilutions of polyclonal serum, 1/50
and 1/100 (orange peak) and 1/200 (blue peak) all bound (37 found on TK1 cells, as
reflected by the shift in the cells' fluorescence intensity. In comparison, the preimmune
serum (brown peak), secondary Ab control (purple peak) and negative control (irrelavant
pAb) (green peak) (Fig. 3B) did not bind TK1 cells.
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(FL2-H). Results are representative of similar results obtained with sera
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Specificity ofpAb sera for (37 WT splenocytes versus [37 K/0

splenocytes

The specificity of the immune sera was further examined by testing on [37 WT
mouse splenocytes (left column) versus [37 K/O mouse splenocytes (right column) (Fig.
4C). Sera that are specific for [37 should not bind [37 K/O splenocytes lacking the
[37 molecule. B cells were excluded from the analysis using anti-B220 Abs conjugated to
FITC, since cell-surface Abs (IgM and IgD) and Fc receptors found on B cells are known
to be responsible for non-specific binding. The preimmune serum sample bound only ~6
% of (37 WT cells. However, a significant percentage of [37 WT cells stained with the
pAb sera shifted to higher fluorescence values (36.5% for Mouse R, 34.9% for Mouse L
and 56.6% for Mouse LR), representing the sera's ability to recognize and bind [37. On
the other hand, there was a significant reduction in [37 K/O cell binding compared to the
[37 WT cell binding by all three pAb sera. The small percentage of [37 K/O cells that
were stained (13.0% for Mouse R, 10.3% for Mouse L and 15.0% for Mouse LR) is
suspected to be non-specific binding or the presence of pAb to non-[37 molecules. Nonspecific binding of the sera can be subtracted resulting in 23.5% of P7 WT cells bound by
Mouse R serum, 24.6% of [37 WT cells bound by Mouse L serum and 41.6% of p7 WT
cells bound by Mouse LR serum. As expected, the positive control did not bind
P7 K/O cells. This assay suggests that the differential binding of the immune pAb to WT
splenocytes but not to K/O splenocytes reflects the pAb sera binding to P7 molecules.

28

B

0 7 Wild-type Mouse Splenocytes
^

Preimmune Serum
•6.4%

07 Knock-out Mouse Splenocytes
_
Preimmune Serum
O1
o
O -j
7c

1<M)

10' 1CT 1(f

B220FITC

FIB504 Positive Control

r*- *- :
on
o
o -

Jc

10" 10' 10' 10° 10^
B220 FITC

FIB504 Positive Control
r,

"~10° 10'B22010'FITC1 0

3

10 M

Mouse R pAb serum

Mouse R pAb serum

13.0 Yc
m %
10" 10' 10' 10° 10
B220FITC

B220FITC

Mouse L pAb serum
21
o
o-

UAm

r-- <=>!
o

34j %
1
|H
)u 101B220FITC
10' 10° 10'
Mouse LR pAb serum

10 c
c
0' 10' 10° 10M
B220FITC

Mouse LR pAb serum

156.64

1
nr' 0 —
io' 1tir '2ic—
B220FITC

102^ 103J 10

B220FITC

FIGURE 4. pAb sera screening on (37 WT versus [37 K/O mouse
splenocytes. A. Unstained splenocytes, gate R2 includes presumed
mononuclear cells. B. The dot plot is gated on R2, region R1 has
mononuclear cells unstained by anti-B220 antibodies conjugated to
FITC. All panels in (C) are gated on R1 and R2, excluding B cells.
PE is conjugated to goat anti-mouse secondary Abs (FL2-H).

29

Determination of immune sera specificity for mouse and human (37
To verify that there was an immune response against human (37 as well as mouse
(37 following the booster with PBMC, flow cytometric assays using a mixture of PBMC
and TK1 cells were performed (Fig. 5). TK1 cells can be distinguished from PBMC on
forward scatter based on size since PBMC are significantly smaller than the TK1 cancer
cells (Fig. 5A). The preimmune serum, secondary Ab control and negative control
(Listeria monocytogenes pAb) only nonspecifically bound both types of cells, with an
average of 6% of TK1 cells and 7% of PBMC being bound for the three mice. The pAb
sera from all three mice bound [37 on the human cells as well as the TK1 cells. The sera
from Mouse LR, R and L bound 37.6%, 40.6% and 77.4% of the human cells and 93.4%,
91.6% and 96.7% of TK1 cells, respectively (Fig. 5B). Two positive controls were used
in this experiment, FEB504 which is a rat anti-(37 mAb that binds both mouse and human
cells and ACT-1, a mouse anti-a4(37 mAb that exclusively binds human cells. Results
indicate that both positive controls behaved as expected and that polyclonal sera Abs
were able to recognize and bind human [37 as well as mouse (37. Flow cytometry was
preferred over ELISA for future screening experiments because two cell types (such as
TK1 cells and PBMC) can be mixed and distinguished in flow cytometry simultaneously
generating information about the sera or supernatants' specificity for both mouse and
human (37.
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HYBRIDOMA YIELD FOLLOWING

FUSION

Three separate fusions were performed sequentially based on the highest pAb titer
of the mouse sera, assessed by several of the experiments described previously. All three
fusions were successful in producing hybridomas. Approximately 795 hybridomas were
obtained from three fusions. Mouse L generated 218 clones while Mouse LR and Mouse
R produced 121 and 456 clones, respectively (Table 1).

Table 1. Summary of hybridoma yield following fusion
Mouse

Total

Single

% Single

Original

Hybridomas

Clones

Clones

Positive

Subcloned

Hybridomas

L

218

115

53%

14

13

LR

121

97

80%

22

11

R

456

302

66%

77

16
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SPECIFICITY OF HYBRIDOMA SUPERNATANTS

FOR MOUSE AND HUMAN (37

Hybridomas were initially screened using ELISA (data not shown) and positive
supernatants were used to stain a mixture of PBMC and TK1 cells in flow cytometric
assays to determine specificity for (37. A majority of the hybridomas were negative for
anti-(37 Ab. However, Mouse L produced 14 hybridomas that responded to the
[37 antigen. Mouse LR and Mouse R produced 22 and 77 positive hybridomas,
respectively (Table 1). A few of the positive hybridomas exhibiting different staining
patterns, G5-H5, F9-D3, D6-E12, B7-E8 and F4-A9 are depicted in Fig. 6 along with an
example of a negative hybridoma. Several of the positive hybridomas were subcloned by
limiting dilution.
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Subclones were retested by flow cytometry and many showed staining patterns
similar to those generated by the original hybridomas. Those that remained positive
(subclones of hybridoma G5-H5, F9-D3, D6-E12, B7-E8 and F4-A9) are examined in
Fig. 7. Judging from their staining patterns, G5-H5 is an example of a clone that binds
TK1 cells only and not PBMC while clone F9-D3 shows the opposite by binding only
PBMC. D6-E12 is a clone that binds both types of cells moderately well. Furthermore,
clones B7-E8 and F4-A9 seemed to produce Abs that recognized (37 well on both types of
cells. Subclone F4-A9 showed higher specificity for the TK1 cells than the original F4A9 hybridoma. An example of a negative subclone from hybridoma F4-A9 that did not
produce anti-(37 Ab is also shown.
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To further investigate the specificity of these clones for (37, supernatants were
also evaluated on (37 WT splenocytes versus (37 K/O mouse splenocytes like the sera
(Table 2). None of the supernatants bound well to the (37 WT cells (represented by mean
fluorescence values in the FL2 channel). The pAb serum also did not respond to the
(37 WT splenocytes as well as it did in previous experiments. Only the positive control
FIB504 bound the (37 WT cells. Furthermore, there was no significant reduction in the
mean fluorescence when the supernatants were applied to (37 K/O cells. The positive
control solely displayed a reduction in the mean fluorescence values when bound to
(37 K/O cells versus being bound to (37 WT cells.
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Table 2. Hybridoma subclone supernatant screening on P7 WT versus
[37 K/O mouse splenocytes 3
Primary
Antibody

p7 WT Splenocytes
FL2 (PE)
Arithmetic Mean
Fluorescence
(Arbitrary Units)

p7 K/O
Splenocytes
FL2 (PE)
Arithmetic Mean
Fluorescence
(Arbitrary Units)

Listeria pAb
(Negative Control)

8.89

16.77

FIB504 Positive
Control

48.45

9.41

Preimmune Serum

13.29

16.50

Mouse R pAb
Serum

28.43

24.40

Subclone G5-H5
supernatant

9.45

17.04

Subclone B7-E8
supernatant

8.89

17.19

Subclone D6-E12
supernatant

13.41

16.53

Subclone F4-A9
supernatant

33.09

40.23

Subclone F9-D3
supernatant

15.53

15.35

a

Binding of anti-|37 Ab found in the subclone supernatants to
splenocytes is represented by mean fluorescence values (arbitrary
units) in the FL2 channel. Goat anti-mouse secondary Abs are
conjugated to PE. B cells were excluded from the flow cytometry
analysis with anti-B220 Abs conjugated to FITC.
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COMPETITION ASSAYS TO ASSESS AB FUNCTION
In order to assess if the Abs produced by these clones were blocking Abs able to
block the positive controls FIB504 (Table 3) and/or ACT-1 (Table 4) from binding [37,
competition assays were performed. The positive control samples were not blocked by
primary Ab. Neither the polyclonal serum nor the supernatants were able to block the
FEB504 Ab from binding [37 on the TK1 cells, since no reduction in mean fluorescence
can be detected compared to the positive control (Table 3). In the competition assay
using ACT-1 Ab, only the FIB504 was able to block the Ab from binding [37 on the
PBMC. This is evident from the reduction of the mean fluorescence in the FIB504
sample. The polyclonal serum as well as the supernatants did not block the ACT-1 Ab,
reflected by the mean fluorescence values remaining consistently high (Table 4). The
results of both competition assays suggest that none of the clones produce blocking Abs

Table 3. FIB504 competition assay to assess the subclone
supernatant Abs' ability to block FIB504 from binding (37 on
TK1 cells 3
Primary Antibody

TK1 cells FL2 (PE) Arithmetic
Mean Fluorescence
(Arbitrary Units)

FIB504 Positive
Control

756.39

Listeria pAb
(Negative Control)

734.41

Preimmune Serum

719.87

Mouse LR pAb Serum

659.34

Subclone G5-H5
supernatant

751.82

Subclone B7-E8
supernatant

735.63

Subclone D6-E12
supernatant

749.28

Subclone F4-A9
supernatant

768.43

Subclone F9-D3
supernatant

750.05

a

Mean fluorescence values (arbitrary units) represent goat
anti-rat secondary Abs (conjugated to PE) binding rat-anti
mouse (37 (FIB504).

Table 4. ACT-1 competition assay to assess the subclone
supernatant Abs' ability to block ACT-1 from binding a4p7 on
PBMC a
Primary Antibody

PBMC
FL4 (APC)
Arithmetic Mean Fluorescence
(Arbitrary Units)

ACT-1 Positive
Control

35.54

FIB504 Positive
Control

11.21

Listeria pAb
(Negative Control)

34.91

Preimmune Serum

34.79

Mouse LR pAb Serum

33.01

Subclone G5-H5
supernatant

33.93

Subclone B7-E8
supernatant

36.62

Subclone D6-E12
supernatant

35.42

Subclone F4-A9
supernatant

32.06

Subclone F9-D3
supernatant

35.57

a

Mean fluorescence values (arbitrary units) represent antia4p7 ACT-1 (directly conjugated to APC) binding PBMC.
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MULTI-COLOR ASSAY TO ASSESS AB BINDING TO A SUBSET OF T CELLS
Finally, the supernatants combined with additional multi-color antibodies were
used to stain PBMC, focusing on CD4+ effector memory T helper cells that migrate to
the gut. These cells are also CD45RA|0VV CD62L low and have suppressed levels of CLA.
The staining patterns of subclone supernatants were compared with the staining pattern
generated by the ACT-1 positive control (Fig. 8, C and D). The supernatants' ability to
bind this specific type of T cell subset and generate a pattern similar to that of the
positive control ACT-1 would indicate the presence of anti-a4|37 antibodies that
recognize the integrin. Compared to the ACT-1 Ab however, the Abs found in the
subclone supernatants and the polyclonal Ab serum generated different staining patterns
on effector memory T cells (Fig. 8, C and D). The ACT-1 showed three distinct
populations indicating the presence of cell populations that specifically migrate to the
gut, the skin or neither (Fig.8D). However, both the polyclonal Ab serum and subclone
supernatants only revealed two distinct populations: one that was CLA negative and
presumably 07 positive and another which was positive for both CLA and (37, which is
unlikely because effector memory T cells would migrate to one or the other destination,
not both.
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Discussion
Along with a dysregulated mucosal immune system, IBD involves constant
recruitment of lymphocytes circulating in the blood to the gut. The a407 integrin
expressed by lymphocytes mediates their binding to the vascular endothelium via the
MAdCAM-1 ligand and facilitates their transmigration into the gut tissue (2). In this
study, an attempt was made to produce an anti-a407 Ab that could potentially be used to
track and study gut-homing lymphocytes associated with IBD, since the only antia407 Ab in existence is not commercially available for research. 07 K/O mice were
immunized with naturally-occurring 07 found on WT mouse splenocytes and PBMC.
The rationale for immunizing with both mouse and human cells was to generate
polyclonal Abs against shared epitopes of mouse and human 07. After an immune
response was confirmed against the 07, hybridoma technology was used to generate
clones secreting anti-07 Abs. Screening assays were optimized to identify and isolate
these hybridomas. The Ab produced, F4-A9, generated different staining patterns than
the positive control, ACT-1 when binding to a subset of T cells that migrate to the gut.
This indicates that the Ab is different from the ACT-1 mAb and unlikely to be anti-a407.
Our results indicate that the immunization strategy was effective in eliciting an
immune response but could be improved. The naturally-occurring cell-surface 07 subunit
on WT mouse splenocytes was immunogenic and induced an immune response in
07 K/O mice as evident by the 07 antigen-specific polyclonal Abs. The post-immune
sera reacted with mouse 07 on TK1 cells and WT splenocytes as well as with human
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07 on PBMC but not with (37 K/O splenocytes. Non-specific binding of the sera to
07 K/O splenocytes may have been due to Abs generated against other epitopes on WT
splenocytes, although ideally the only difference between the [37 WT mice and the K/O
mice should have been the 07 molecule found on WT mouse cells.
The immune response was good but the number of plasma cells secreting anti07 Abs could be enhanced through several avenues such as increasing the frequency and
number of immunizations or exploring other modes of antigen administration (19). In
addition, alternative immunogens can be used such as synthetic 07 peptides conjugated to
carrier proteins or T lymphoma cells over-expressing a407 (TK1).
The success of the next step in 07 specific mAb production, the fusion, relied on
the successful union of myeloma cells with highly-specific plasma cells. Many factors
regarding the two cells types must be accounted for in order to generate the desired
number of hybridomas. An average of 265 hybridomas per fusion were obtained.
Although a reasonable number, it could be increased with an improved technique.
Essentially, the best way to get a better yield of anti-07 Ab producing hybridomas would
have been to have the optimal number of 07 specific plasma cells, rather than naive B
cells, available at the time of fusion. Furthermore, the ratio of the two cell types during
the fusion is also an important factor in generating hybridomas (20). We used a 1:3 ratio
of Sp2/0 myeloma cells to splenocytes, although the ideal is 1:2. This may have affected
our fusion, since there were many more splenocytes than their myeloma partners. Yet
other factors influencing the fusion are the handler's technical experience and conditions
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during the fusion. Gentle handling combined with the optimum temperature and media
will ensure the survival of cells through stressful conditions.
Once the hybridomas were screened for (37 specificity, staining patterns of PBMC
and TK1 cells were evaluated. Hybridoma supernatants stained the cells differentially.
In some cases, for example hybridoma G5-H5, two distinct populations, one positive and
the other negative for (37, were observed. More than one Ab might be present in the
supernatants from these hybridomas, requiring subcloning. Additionally, since the cells
may not all be in identical stages of the cell cycle, a dividing population may exhibit
differential expression of cell-surface antigens. In some other cases, a range was
observed in PBMC and TK1 cell staining. This can be explained as cells binding the Abs
with different intensities due to the epitopes for Ab binding not being exposed the same
on all cells.
When the supernatants were examined on (37 WT versus (37 K/O splenocytes,
overall low fluorescence values and no reduction in binding to K/O cells was observed.
This could be attributed to low Ab concentration, or it could mean the hybridomas lost
the ability to produce Ab. Moreover, the pAb serum did not function as well as it did in
previous experiments. Freeze-thaw cycles may have affected the integrity of the
polyclonal Abs.
Functional analyses demonstrated that the Abs could not inhibit positive control
Abs from binding (37. This could mean that these Abs bound different epitopes than the
positive control Abs and therefore could not block. It could also mean that the Abs were
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not blocking Abs, or it is possible that the supernatants again had low concentrations of
Ab or no Ab at all.
Finally, the Abs were tested for binding to effector memory T cells known to
migrate to the gut, and staining patterns were compared to those of the well-established
ACT-1 mAb. Effector memory T cells that migrate to the gut have a407, and those that
migrate to the skin have CLA. Effector memory T cells stained with ACT-1 showed
three populations, effector memory T cells that have CLA and migrate to the skin, those
that do not have CLA but rather a 4 0 7 and migrate to the gut, and some that have neither.
In the polyclonal Ab serum and the mAb samples, however, only two populations were
observed: one that seemed positive for (37 but not CLA and another that seemed positive
for both. The latter population is unusual because effector memory cells would express
one type of homing molecule and suppress the other, resulting in migration to the gut or
skin, not both. This indicates that the Abs in the polyclonal Ab serum as well as the
mAbs are different from ACT-1 and unlikely to be anti-a4(37.
In summary, this paper describes a novel immunization strategy to generate an
a4(37 mAb and the development of screening procedures to isolate specific anti-(37
secreting hybridomas. Further work will be needed to identify additional 07 specific
hybridomas and stabilize mAb production in culture. Methods to optimize the immune
response need to be evaluated. A better immune response, composed of Abs with
improved 07 specificity, will make improved identification and isolation of hybridomas
producing highly-reactive Abs with the desired specificity for 07.
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DISCUSSION
Along with a dysregulated mucosal immune system, IBD involves constant
recruitment of lymphocytes circulating in the blood to the gut. The a4(37 integrin
expressed by lymphocytes mediates their binding to the vascular endothelium via the
MAdCAM-1 ligand and facilitates their transmigration into the gut tissue (4). In this
study, we attempted to produce an anti-a4(37 Ab that could potentially be used to track
and study gut-homing lymphocytes associated with IBD, since the only anti-a4[37 Ab in
existence is not commercially available for research. p7 K/O mice were immunized with
naturally-occurring P7 found on WT mouse splenocytes and PBMC. The rationale for
immunizing with both mouse and human cells was to generate polyclonal Abs against
shared epitopes of mouse and human p7. After an immune response was confirmed
against the (37, hybridoma technology was used to generate clones secreting anti-P7 Abs.
Screening assays were optimized to identify and isolate these hybridomas. The antibody
produced generated different staining patterns than the positive control, ACT-1 when
binding to a subset of T cells that migrate to the gut.
Our results indicate that the immunization strategy was effective in eliciting an
immune response but could be improved. The naturally-occurring cell-surface P7 subunit
on WT mouse splenocytes was immunogenic and induced an immune response in
P7 K/O mice as evident by the P7 antigen-specific polyclonal Abs. The post-immune
sera reacted with mouse p7 on TK1 cells and WT splenocytes as well as with human
P7 on PBMC but not with p7 K/O splenocytes. Non-specific binding of the sera to
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(37 K/O splenocytes may have been due to Abs generated against other epitopes on WT
splenocytes, although ideally the only difference between the (37 WT mice and the K/O
mice should have been the (37 molecule found on WT mouse cells.
The immune response was good but the number of plasma cells secreting anti(37 Abs could be enhanced through several avenues. First, the mice can be exposed to
more of the antigen by increasing the number of splenocytes used for the immunizations
or increasing the frequency and number of immunizations. Second, other modes of
antigen administration can be explored, such as injecting footpads associated with lymph
nodes rather than the s.c. or i.p. methods commonly targeting the spleen. Finally,
alternative immunogens can be used such as synthetic (37 peptides conjugated to carrier
proteins. Abs generated by synthetic peptide antigens have the advantage of binding
denatured proteins. However, unlike whole cell generated Abs they may not bind
globular proteins and have limited function (29). In contrast, Abs generated to whole
cells may have a broader range of functional activities. The Abs can be fluorescentlytagged and used to stain cells expressing the epitope of interest and/or they can be used to
block receptor/ligand interactions. If immunizations with whole cell antigens are
continued for this study, immunizations with T lymphoma cells over-expressing
a4(37 (TK1) can be used as an alternative. However, the cells would need to be treated
with mitomycin C to repress cell growth prior to the immunizations.
The success of the next step in (37 specific mAb production, the fusion, relied on
the successful union of myeloma cells with highly-specific plasma cells. Many factors
regarding the two cells types must be accounted for in order to generate the desired
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number of hybridomas. We obtained an average of 265 hybridomas per fusion.
Although a reasonable number, it could be increased with an improved technique.
Essentially, the best way to get a better yield of anti-P7 Ab producing hybridomas would
have been to have the optimal number of [37 specific plasma cells, rather than naive B
cells, available at the time of fusion. More sources of plasma cells such as lymph nodes
could have been sought along with the spleen. P7 specific plasma cells could also have
been enriched by passing the splenocytes through column chromatography, with
P7 molecules attached to column beads. In addition, P7 specific plasma cells could be
sorted using fluorescently-tagged P7. Furthermore, the ratio of the two cell types during
the fusion is also an important factor in generating hybridomas (30). We used a 1:3 ratio
of Sp2/0 myeloma cells to splenocytes, although the ideal is 1:2. This may have affected
our fusion, since there were many more splenocytes than their myeloma partners.
Moreover, it was once believed the histocompatible relatedness of the two types of cells
being fused plays a role on hybridoma stability (30). Our fusion also involved cells from
two different strains of mice; C57BL/6 splenocytes were fused with Sp2/0 myeloma cells
originating from a BALB/c mouse. The average of 265 hybridomas per fusion may have
been higher if cells from the same strains had been used for the fusion. Yet other factors
influencing the fusion are the handler's technical experience and conditions during the
fusion. Gentle handling combined with the optimum temperature and media will ensure
the survival of cells through stressful conditions. Hybridoma yield could have also been
influenced by our plating method since we tried to obtain the maximum number of single
clones by plating different concentrations of the fused cells. Although we were able to
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get high percentages of single clones, this perhaps compromised our overall yield of
positive hybridomas.
Screening assays need to be optimized for the identification and isolation of anti(37 Ab-producing hybridoma cell lines. These assays must be able to process hundreds of
samples simultaneously and identify positive clones within 48 hours (29). They must
also be proven to be specific and sensitive for the antigen-Ab reaction. The ELISA,
using TK1 cells, was able to process multiple samples; however, it was not as sensitive as
the flow cytometry assays. Furthermore, unlike flow cytometry, in the ELISA, PBMC
could not be mixed with TK1 cells to provide information simultaneously on both antihuman and anti-mouse (37 Abs. Although flow cytometry has these advantages, a
disadvantage of flow cytometry is that samples can be prepared only in FACS tubes.
This limits the number of samples that can be analyzed. Overall, our screening assays
were reliable and reproducible; however, we need an assay that will combine efficiency
with sensitivity.
Once the hybridomas were screened for (37 specificity, staining patterns of PBMC
and TK1 cells were evaluated. Hybridoma supernatants stained the cells differentially.
In some cases, for example hybridoma G5-H5, two distinct populations, one positive and
the other negative for (37, were observed. More than one Ab might be present in the
supernatants from these hybridomas, requiring subcloning. Additionally, since the cells
may not all be in identical stages of the cell cycle, a dividing population may exhibit
differential expression of cell-surface antigens. In some other cases, a range was
observed in PBMC and TK1 cell staining. This can be explained as cells binding the Abs
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with different intensities due to the epitopes for Ab binding not being exposed the same
on all cells.
When the supernatants were examined on (37 WT versus (37 K/O splenocytes,
overall low fluorescence values and no reduction in binding to K/O cells was observed.
This could be attributed to low Ab concentration, or it could mean the hybridomas lost
the ability to produce Ab. Moreover, the pAb serum did not function as well as it did in
previous experiments. Freeze-thaw cycles may have affected the integrity of the
polyclonal Abs.
Functional analyses demonstrated that the Abs could not inhibit positive control
Abs from binding (37. This could mean that these Abs bound different epitopes than the
positive control Abs and therefore could not block. It could also mean that the Abs were
not blocking Abs, or it is possible that the supernatants again had low concentrations of
Ab or no Ab at all. The hypothesis that the hybridomas lost the ability to produce Abs
needs to be further examined.
Some clones may have lost the ability to produce Ab as a result of being in culture
for an extended period of time. The stability of the clones in terms of Ab production may
have been compromised due to high cell density (30). High cell density can lead to
buildup of toxic waste material and competition for nutrients, and eventually cells may
begin to self-regulate their growth and enter a lag phase. Some hybridomas may stop
producing Ab, once they have experienced this event. In addition, studies have shown
that cell proliferation and Ab production are not necessarily correlated (31). Even though
some clones looked healthy and grew well, conditions for Ab production might not have
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been met. Ideal serum concentrations, for example, have been shown to be different for
cell growth versus Ab production. FCS was reduced to 10% from the original 20% in
order to wean the cells from serum dependency. This sudden change could have led to a
drop in Ig secretion. A more gradual change would have been preferred to allow the cells
to adapt.
Loss of function of Ab-producing hybridomas can also be attributed to the
unstable nature of the hybrid cell chromosome. Although it might not be true for our
allogeneic fusion, it has been shown that in xenogeneic fusions the non-mouse myeloma
genes compete with the mouse heavy chain immunoglobulin locus on the B cell
chromosome for expression (30). In fact, the myeloma chromosome may even repress
the B cell chromosome from translating Abs and go as far as to prevent replication of Ab
genes. These explanations provide insight into our hybridomas' lack of ability to produce
Ab. The next time we handle antibody-secreting hybridomas, we would ensure the
clones are screened while they are in log phase of growth before they enter a lag phase
and stop producing Ab.
Finally, the Abs were tested for binding to effector memory T cells known to
migrate to the gut, and staining patterns were compared to those of the well-established
ACT-1. Effector memory T cells that migrate to the gut have oc4p7, and those that
migrate to the skin have CLA. Effector memory T cells stained with ACT-1 showed
three populations, effector memory T cells that have CLA and migrate to the skin, those
that do not have CLA but rather a407 and migrate to the gut, and some that have neither.
In the polyclonal Ab serum and the mAb samples, however, only two populations were
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observed: one that seemed positive for (37 but not CLA and another that seemed positive
for both. The latter population is unusual because effector memory cells would express
one type of homing molecule and suppress the other, resulting in migration to the gut or
skin, not both. This indicates that the Abs in the polyclonal Ab serum as well as the
mAbs are different from ACT-1 and unlikely to be anti-a4b7.
Once an anti-|37 Ab is identified from the hybridomas, it can be characterized and
its function further analyzed. Like the competition assays where the Abs were tested for
the ability to block positive controls from binding [37, a chemotaxis assay can prove
useful in assessing Ab function. This assay can test if the anti-a4[37 Ab is able to inhibit
gut-specific cells expressing a4[37 from migrating to the a4(37 ligand, MAdCAM-1, thus
interfering with interaction essential for gut-homing.
An anti-a4(37 Ab may be used to test the hypothesis that IBD is associated with
elevated blood levels of gut-homing plasmablasts. Plasmablasts are premature plasma
cells that express a4[37 if they are destined to migrate to the gut. This Ab would be able
to track and quantify gut-specific plasmablast levels in patient blood samples and monitor
how the levels change in response to commonly-used therapies against IBD. This would
be accomplished by FACS analysis of PBMCs from IBD patients using plasmablast
markers such as CD 19+, CD38+, CCR10 and CCR9 along with the a4[37 integrin. CD 19
and CD38 are markers found on plasma cells, while CCR10 and CCR9 are involved in
cell trafficking and migration to sites of inflammation. Additionally, it is important to
observe plasmablasts in the blood, because several cases of IBD treated with antiT N F a mAb have resulted in rare and fatal plasmablast lymphomas (32). Studying
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plasmablasts may shed light on more aspects of the commonly used anti-TNFa mAb
treatment. An anti-a407 Ab would provide the means to look into these clinical and
research issues.
In summary, this paper describes a novel immunization strategy to generate an
a407 mAb and the development of screening procedures to isolate specific anti-07 Absecreting hybridomas. Further work will be needed to identify additional 07 specific
hybridomas and stabilize mAb production in culture. Methods to optimize the immune
response need to be evaluated. A better immune response, composed of Abs with
improved 07 specificity, will make improved identification and isolation of hybridomas
producing highly-reactive Abs with the desired specificity for 07.
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s e c o n d a r y s o u r c e s n e e d s to be ensured.
T h i s registration includes continued m o n i t o r i n g o f your research by the
Board to assure that the subjects are being a d e q u a t e l y and p r o p e r l y
protected f r o m such risks. If at any time a subject b e c o m e s injured or
c o m p l a i n s of injury, you must notify Dr. P a m e l a S t a c k s . Ph.D.
i m m e d i a t e l y , injury includes but is not limited to bodily h a r m ,
psychological t r a u m a , and release of potentially d a m a g i n g personal
i n f o r m a t i o n . This approval for the h u m a n s u b j e c t ' s portion o f your project
i.s in effect for one year, and data collection b e y o n d February 25, 2010
requires an extension request.
If vou have any questions, please contact m e at ( 4 0 S i 9 2 4 - 2 4 2 7 .
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